Non-Hodgkin Lymphoma (NHL)

Latest News

Multigenerational | Image Credit: © DisobeyArt-stock.adobe.com

DLBCL Outcomes Vary Sharply for Patients 80 Years and Older

By Maggie L. Shaw

April 16th 2025

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.

CAR T in NHL | Image Credit: © LASZLO-stock.adobe.com

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

By Maggie L. Shaw

April 3rd 2025

Amid NIH Cuts, ASH Expands Eligibility for Midcareer Research Awards

By Mary Caffrey

March 24th 2025

CAR T | Image Credit: © Funny-stock.adobe.com

Overcoming CAR T Manufacturing Failure in LBCL

By Maggie L. Shaw

March 21st 2025

Patients with R/R transformed DLBCL have modest 4-year event free and overall survival rates under 50%, making disease management a persistent challenge | SuriyaPhoto - stock.adobe.com

Atezolizumab, Immunogenic Chemotherapy Combination Shows Promise for DLBCL Treatment

March 14th 2025

Continuing Medical Education

April 19th 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

April 19th 2025

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer

April 19th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology

April 19th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

More News

Lymphoma diagnosis | Image Credit: © Vitalii Vodolazskyi - stock.adobe.com

July 10th 2024

DA-EPOCH-Rituximab: Successfully Treating PMBCL in a Transgender Woman

Gayle Turim Dickstein

A case study describes the disparate factors that played into the chemotherapy and other treatment decisions made by a team in Japan when addressing their patient’s primary mediastinal large B-cell lymphoma (PMBCL).

CART and gene therapy | Image Credit: ArtemisDiana-stock.adobe.com

July 9th 2024

Late Effects of CAR T-Cell Therapy in Lymphoma

Kimberly Rath, PharmD

In this new analysis, investigators review the late adverse events associated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.

non-Hodgkin lymphoma | Image Credit: MQ-Illustrations-stock.adobe.com

July 6th 2024

Study to Quantify Non-Hodgkin Lymphoma Risk in HIV

Karen Jacobson-Sive

This meta-analysis study will estimate the global and regional burden of HIV-associated non-Hodgkin lymphoma to aid the development of prevention and control strategies.

DLBCL | Image Credit: Image Credit: laszlo-stock.adobe.com

July 1st 2024

ViPOR: Novel Targeted Therapy Combination Shows Potential in Relapsed DLBCL

Gayle Turim Dickstein

The 5 agents in ViPOR—including venetoclax and lenalidomide—worked better together in a phase 1b/2 trial than they previously have, individually, in treating patients with certain diffuse large B-cell lymphoma (DLBCL) subtypes.

FDA approved | Image credit: ArtEternal – stock.adobe.com

June 27th 2024

Epcoritamab Gets Label Expansion for Difficult-to-Treat R/R Follicular Lymphoma

Hayden E. Klein

The FDA approved epcoritamab-bysp to treat adults with relapsed or refractory (R/R) follicular lymphoma after 2 or more lines of systemic therapy.

microscopic image of DLBCL | Image Credit: David A Litman-stock.adobe.com

June 17th 2024

Polatuzumab Vedotin: Review Spotlights Its Use, Promise in DLBCL

Gayle Turim Dickstein

With its recent approvals around the world to treat newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the antibody-drug conjugate polatuzumab vedotin is changing regimens for current and future patients, with manageable adverse effects.

Medical technology | Image credit: ipopba - stock.adobe.com

June 14th 2024

Dr Catherine Diefenbach on the Evolving DLBCL Treatment Landscape

Catherine Diefenbach, MD, an American Society of Hematology expert and director of the Clinical Lymphoma Program at NYU Langone's Perlmutter Cancer Center, discussed the evolving state of diffuse large B-cell lymphoma (DLBCL) therapeutics and exciting areas of research.

Case Reports: Managing DLBCL Associated With Papillary Thyroid Carcinoma

June 12th 2024

Case Reports: Managing DLBCL Associated With Papillary Thyroid Carcinoma

Kimberly Rath, PharmD

Case reports and systematic review found the combination of surgery, chemotherapy, and radiotherapy can effectively manage diffuse large B-cell lymphoma (DLBCL) associated with papillary thyroid carcinoma.

Stethoscope chart graph data | Image Credit: © amazing studio - stock.adobe.com

June 7th 2024

Obinutuzumab and Radiation Combo Shows Promise for Refractory DLBCL

Kimberly Rath, PharmD

A small retrospective study found that combining obinutuzumab with radiation therapy may offer a viable and well-tolerated treatment option for patients with refractory diffuse large B-cell lymphoma (DLBCL).

dlbcl | Image Credit: laszlo-stock.adobe.com

June 3rd 2024

How the Tumor Microenvironment Affects DLBCL Prognosis, Treatment

Gayle Turim Dickstein

Further acknowledgement and study of the tumor microenvironment in diffuse large B-cell lymphoma (DLBCL) could eventually result in much more personalized—and effective—treatments.

Lymphoma word block image | Image Credit: © airdone - stock.adobe.com

May 27th 2024

Key Features of Rare Fibrin-Assisted Diffuse Large B-Cell Lymphoma

Kimberly Rath, PharmD

A case study details the cytological and histological features of fibrin-assisted diffuse large B-cell lymphoma in a patient with no clinical symptoms, highlighting the diagnostic challenges of this condition.

Nurse holding older woman's hands | Image Credit: © Cecilie Arcurs/peopleimages.com - stock.adobe.com

May 24th 2024

IVIG Shows Promise in Protecting Older Patients With Lymphoma From COVID-19

Kimberly Rath, PharmD

Prophylactic intravenous immunoglobulin reduces COVID-19 infection rates in older patients with DLBCL with hypogammaglobulinemia undergoing reduced-intensity R-CHOP therapy.

Photomicrograph of a diffuse large B-cell lymphoma | Image Credit: ©DavidALitman - stock.adobe.com

May 16th 2024

Patient/Physician Teamwork: Treating a Rare Oral Presentation of DLBCL

Gayle Turim Dickstein

A very unusual case of lip-based diffuse large B-cell lymphoma (DLBCL) was treated successfully thanks to prompt diagnosis and chemotherapy treatments.

Health costs | Image credit: utah51 - stock.adobe.com

May 8th 2024

Study: Care Costs for R/R DLBCL Increase With Each Line of Therapy

Jared Kaltwasser

New therapies are helping patients, but are also driving up overall costs of care.

Lymphoma graphic | Image Credit: © MP Studion - stock.adobe.com

May 2nd 2024

Much-Improved Outcomes for Follicular Lymphoma Transformed to DLBCL in the Rituximab Era, Study Finds

Gayle Turim Dickstein

Although histological transformation to diffuse large B-cell lymphoma (DLBCL) remains a common complication of follicular lymphoma, patient survival has increased significantly since the introduction of rituximab about 2 decades ago.

IV chemotherapy | Image Credit: Aidman - stock.adobe.com

April 24th 2024

Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL

Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).

Doctors discussing a case | Image Credit: DelmaineDonson - stock.adobe.com

April 18th 2024

Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes

Kimberly Rath, PharmD

A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.

Liquid biopsy | Image Credit: ArtemisDiana - stock.adobe.com

April 13th 2024

Liquid Biopsy Whole-Genome Sequencing Optimizes MRD Detection in DLBCL

Using the newly created MAESTRO-Pool tool, whole genome sequencing revealed DNA that could be used to more effectively detect minimum residual disease (MRD) in patients who have diffuse large B-cell lymphoma (DLBCL).

Lymphoma diagnosis | Image Credit: Vitalii Vodolazskyi - stock.adobe.com

April 9th 2024

CAR T-Cell Therapy Effective in Older Patients With DLBCL

Overall survival and complete response rates were comparable across a younger and an older cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Malignant effusion cytology microscopic image of diffuse large B-cell lymphoma a type of non Hodgkin lymphoma | Image credit: David A Litman - stock.adobe.com

April 1st 2024

Older Patients With DLBCL Face Poor Overall Survival, High Costs With R-GemOx Treatment

Treatment with R-GemOx was associated with significant health care resource utilization, high costs surrounding treatment, and low overall survival in elderly patients with diffuse large B-cell lymphoma (DLBCL).

FDA | Image credit: wladimir1804 - stock.adobe.com

March 25th 2024

FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma, R/R DLBCL

The FDA issued complete response letters (CRLs) for the biologics license application for odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (DLBCL).

Magnified image of a cytokine storm | Image Credit: © nobeastsofierce - stock.adobe.com

March 19th 2024

Bispecific Antibodies Represent DLBCL Treatment Breakthrough

Analysis of single-agent, combination, and novel bispecific antibodies revealed a positive landscape of treatment for patients with diffuse large B-cell lymphoma (DLBCL).

Photomicrograph of a diffuse large B-cell lymphoma a type of non-Hodgkin lymphoma | Image Credit: DavidALitman - stock.adobe.com

March 15th 2024

Radiotherapy May Boost Survival for Certain Patients With DLBCL

Jared Kaltwasser

Patients had a lower risk of their diffuse large B-cell lymphoma (DLBCL) progressing if they had consolidative radiotherapy, a new report shows.

Patient in the hospital - Tyler Olson -stock.adobe.com.jpg

March 9th 2024

Predictive Model Can Assess Risk of Febrile Neutropenia in Patients Undergoing Chemotherapy for DLBCL

Investigators used a predictive model factoring in lymphopenia, elevated SIL2R level, extranodal involvement, and a positive hepatitis panel to determine risk for febrile neutropenia among patients with diffuse large B-cell lymphoma (DLBCL).

Case study graphic | Image credit: onephoto - stock.adobe.com

February 29th 2024

R-CHOP Leads to Positive Outcome in Rare Case of Collision Lymphoma

Jared Kaltwasser

The patient had both classical Hodgkin lymphoma and diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma - David A Litman - stock.adobe.com

February 28th 2024

Review Highlights Potential for Bispecific Antibodies in DLBCL

Investigators are optimistic about bispecific antibodies (BsAbs) for patients with diffuse large B-cell lymphoma (DLBCL), especially the possibility of combining different BsAbs with distinct targets for stronger treatment outcomes.

Doctor checking an older mans lungs | Image credit: DC Studio-stock.adobe.com

February 23rd 2024

Case of Primary Hepatic DLBCL Following COVID-19 Raises Questions About Possible Links

Jared Kaltwasser

Other viral infections, including Epstein-Barr virus and hepatitis C, have already been linked with primary hepatic lymphoma, the authors said.

Rituximab | Image credit: MQ-Illustrations - stock.adobe.com

February 20th 2024

Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL

Cameron Santoro

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

CAR T cell therapy rendering | Image Credit: © AIGen - stock.adobe.com

February 12th 2024

Meta-Analysis Highlights Differing CAR T Outcomes, Toxicities in Relapsed or Refractory DLBCL

A real-world comparison of 2 chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel and tisagenlecleucel—suggests the former is associated with better efficacy but higher toxicity.

A scientist working with microfluidic devices | Image credit: Наталья Евтехова - stock.adobe.com

February 4th 2024

Study: Microfluid Platform Can Help Screen Novel DLBCL Therapies

Jared Kaltwasser

The authors say their 3D model improves on results using traditional 2-dimensional approaches.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions